Medinno develops cell therapeutics utilizing human stem cells to create targeted treatments for brain diseases such as hypoxic-ischemic encephalopathy and spinal cord injury. Their proprietary technology aims to provide effective neuro-regenerative solutions that address critical gaps in current therapeutic options for these conditions.
Funding
$28.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for brain diseases like hypoxic-ischemic encephalopathy (HIE) and spinal cord injury (SCI) often fall short in providing effective neuro-regeneration, leaving critical gaps in patient care. These conditions can result in significant neurological deficits, highlighting the need for innovative therapeutic approaches.
Solution
Medinno is developing cell therapeutics based on human stem cells to create targeted treatments for neurological disorders. Their approach involves differentiating mesenchymal stem cells (MSCs) into neural stem cells (NSCs) to promote neuro-regeneration in conditions such as HIE and SCI. The company's lead candidate, HIEstem, is being developed for HIE and intraventricular hemorrhage (IVH) in premature infants, while ahNSC is in development for SCI and stroke. Medinno's technology aims to address the underlying causes of neurological damage by providing cells that can replace damaged tissue and restore function.
Target Audience
The primary target audience includes patients suffering from brain diseases such as hypoxic-ischemic encephalopathy, intraventricular hemorrhage, spinal cord injury, and stroke, as well as the healthcare providers who treat these conditions.
Features
- HIEstem: Cell therapy candidate for hypoxic-ischemic encephalopathy (HIE) and intraventricular hemorrhage (IVH)
- ahNSC: Cell therapy candidate for spinal cord injury (SCI) and stroke
- Utilizes human mesenchymal stem cells (MSCs) differentiated into neural stem cells (NSCs)
- Focus on neuro-regenerative solutions for brain diseases